GYRE
Gyre Therapeutics Inc.
7.00$
+4.1%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.7% | 12.4% | 10.6% | -22.2% | 6.6% | -9.9% | -0.6% | 7.0% | 15.3% | -15.1% | 14.1% | -57.5% | -12.1% | |
| 0.6% | 1.1% | 1.5% | 0.9% | 1.8% | 1.7% | 2.4% | 2.2% | 2.1% | 1.8% | 3.0% | 5.1% | 2.9% | |
| 0.3% | 26.8% | 0.0% | 0.1% | 0.9% | 2.0% | 2.3% | 3.0% | 3.8% | 12.4% | 11.5% | 7.1% | 8.7% | |
| -1.9% | 5.4% | -10.1% | -29.3% | -7.6% | -13.0% | -15.2% | -1.0% | -8.0% | -25.4% | 42.2% | 15.7% | 1.8% | |
| 6.2% | 8.6% | 0.9% | 5.8% | 2.7% | 2.7% | 3.7% | 0.9% | 2.2% | 0.4% | 0.8% | 4.4% | 1.9% | |
| -16.9% | 4.9% | -26.6% | -32.8% | -9.4% | -7.2% | 8.9% | -10.2% | -4.1% | 5.0% | -13.6% | 33.5% | 6.1% | |
| 4.7% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -4.6% | 9.2% | 2.4% | 1.1% | 1.5% | 3.5% | 6.1% | 75.2% | 1.2% | 0.9% | 0.1% | 0.0% | 0.6% | |
| 7.3% | 27.4% | -13.7% | -54.3% | -0.9% | -14.5% | 14.7% | 72.1% | 12.8% | -9.0% | 1.9% | 19.9% | 5.7% | |
| 17.5% | 3.8% | 9.8% | -28.0% | 3.9% | -12.6% | -4.3% | 6.1% | 13.1% | -15.5% | 13.3% | -61.9% | -14.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.